The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 10, 2021
Filed:
Sep. 22, 2017
Sichuan Kelun-biotech Biopharmaceutical Co., Ltd., Chengdu, CN;
Jiaqiang Cai, Chengdu, CN;
Qiang Tian, Chengdu, CN;
Mingliang Zhao, Chengdu, CN;
Hong Zeng, Chengdu, CN;
Hongmei Song, Chengdu, CN;
Nan Yu, Wenjiang, CN;
Hua Deng, Chengdu, CN;
Wei Zhong, Chengdu, CN;
Long Yang, Chengdu, CN;
Lei Wu, Chengdu, CN;
Haitao Huang, Chengdu, CN;
Yongyong Wu, Chengdu, CN;
Donghai Su, Chengdu, CN;
Xin Zhou, Chengdu, CN;
Yuting Tan, Chengdu, CN;
Lichun Wang, Chengdu, CN;
Jingyi Wang, Chengdu, CN;
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD., Chengdu, CN;
Abstract
The invention relates to a polyamide compound and a use thereof. Specifically, the invention relates to a type of polyamide compound (which preferably comprise one or more amide bonds formed by condensation of same or different L-amino acids or D-amino acids), or stereoisomers, crystalline polymorphs, solvates, metabolites, prodrugs or pharmaceutically acceptable salts or esters thereof, or pharmaceutical compositions thereof, as well as a method for preparing the polyamide compound and a use thereof in the prevention or treatment of diseases associated with κ-opioid receptor. The polyamide compound of the invention has excellent κ-opioid receptor agonistic activity and hydrophilicity, thus having a lesser ability of penetrating the blood-brain barrier and a lower capacity for entering the brain. The compound of the invention has higher selectivity for a κ-opioid receptor, lower addictiveness, improved pharmacokinetic properties, and improved safety (lower toxicity and/or fewer side effects), good patient compliance, and/or lesser propensity for developing tolerance, among other excellent medicinal properties.